Nalecol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nalecol

Property Description
Active ingredient Ezetimibe
Form Oral tablets
Pharmacological class Selective cholesterol absorption inhibitor
General purpose To help reduce elevated serum cholesterol levels
Origin Synthetic (2-Azetidinone derivative)

What Type of Medicine is Nalecol and What is it Made Of?

Nalecol is a prescription-only medicine containing the active compound Ezetimibe, and it is classified as a hypolipidemic agent used to help lower elevated blood fat levels. The preparation is administered orally in the form of tablets.

The core substance, Ezetimibe, is a synthetic 2-Azetidinone derivative, meaning it is a compound specifically engineered, not naturally sourced, to achieve its targeted effect. This drug is categorized within the distinct pharmacological class known as selective cholesterol absorption inhibitors. As a product marketed under the Nalecol name, it serves as a single-ingredient product, though its therapeutic efficacy means it is often used as a crucial component in combination therapy alongside other lipid-lowering drugs, such as statins, to manage hypercholesterolemia.


How Does Nalecol Differ from Other Cholesterol Medications?

Nalecol's action is unique among common treatments because it functions by targeting and reducing the intestinal absorption of cholesterol rather than inhibiting the body's cholesterol production, which is the primary mode of action for statins. This primary distinction allows the medication to work directly in the digestive system, where it specifically blocks a key protein necessary for taking in cholesterol from both dietary sources and bile.

This mechanism ensures that less cholesterol enters the circulation in the first place, providing a reliable path for maintaining healthy blood lipid levels. The general benefit is a targeted reduction in the overall body cholesterol load, making it particularly useful when a patient needs additional assistance beyond standard therapies or cannot tolerate those treatments. Its specific action offers clinicians a specialized, effective tool to support cardiovascular health.

Regulatory References

  1. NIH Drug Record: Ezetimibe
  2. MedlinePlus Ezetimibe Drug Profile

What side effects are possible with Nalecol?

Possible side effects and safety information

The safety profile of Nalecol (Ezetimibe) is classified by regulatory authorities based on observed frequency in clinical studies and post-marketing surveillance. Adverse reactions are grouped by System-Organ Class (SOC).

Frequency Classification of Adverse Reactions

Frequency Examples of Officially Documented Adverse Reactions
Common (occurring in ge 1 in 100 people) Upper respiratory tract infection, Headache, Diarrhoea, Abdominal pain, Fatigue, Myalgia (muscle pain), Arthralgia (joint pain).
Uncommon (occurring in ge 1 in 1,000 people) Hypertension (high blood pressure), Nausea, Dyspepsia (indigestion), Muscle spasms, Back pain, Increased Blood Creatine Phosphokinase (CPK), Abnormal Liver Function Tests.
Not Known (Post-marketing) Thrombocytopaenia, Pancreatitis, Hepatitis, Cholelithiasis (gallstones), Rhabdomyolysis (severe muscle breakdown), Anaphylaxis, and Severe Cutaneous Adverse Reactions (SCARs).

Serious Adverse Reactions and Safety Constraints

The regulatory label documents potentially serious adverse reactions. These include Myopathy and the more severe Rhabdomyolysis, especially when Ezetimibe is used in combination with statins or fibrates. Persistent, unexplained elevations of Hepatic Transaminases (liver enzymes) are also noted. Rare but critical post-marketing events include severe hypersensitivity reactions like Anaphylaxis and SCARs, such as Stevens-Johnson syndrome.

Specific safety constraints are defined for certain populations. The medicine is not recommended for use in patients with moderate to severe hepatic impairment. Additionally, use with certain fibric acid derivatives is not generally recommended due to an increased documented risk of cholelithiasis.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation confirms that the overdosage profile for the active ingredient, Ezetimibe, is concise and primarily focuses on management. Clinical trials involving doses up to 50 mg per day and an accidental single-patient overdose of 120 mg daily for 28 days were reported to be generally well tolerated without significant clinical adverse effects or laboratory abnormalities. Consequently, there are no specific, unique clinical signs listed in regulatory overdose sections for Ezetimibe alone.

Mandatory Emergency Actions

Due to the lack of a known specific antidote, the regulatory guidance for a suspected overdose requires immediate action. Treatment must be symptomatic and supportive. You must seek immediate medical attention for a known or suspected overdosage. The official prescribing information mandates that if severe symptoms occur, such as collapse, seizure, or trouble breathing, you should immediately call emergency services (e.g., 911). Additionally, healthcare providers are directed to consider contacting a certified Poison Help line or a medical toxicologist for specific management advice.

Therapeutic Uses of Nalecol

What Nalecol Treats: Main Uses and Benefits

Nalecol is generally used as an adjunctive therapy primarily focused on helping address high levels of harmful blood fats. Its main therapeutic role is in supporting the management of cardiovascular risk factors by assisting with the lowering of key lipid markers. The medication is considered relevant for use in conditions such as primary hypercholesterolemia, mixed hyperlipidemia, Homozygous Familial Hypercholesterolemia (HoFH), and Homozygous Sitosterolemia.


Targeting Elevated “Bad” Cholesterol (LDL-C) and Therapeutic Scenarios

Nalecol is commonly used to address persistently high levels of Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol in the blood, known clinically as hypercholesterolemia. The core therapeutic role contributes to the management of these markers, assisting high-risk patients in working toward their medically-defined lipid goals, and contributing to the management of long-term cardiovascular risk factors.

The medication is applied in clinical settings when cholesterol levels remain elevated despite the use of other lipid-lowering therapies, or when other lipid-lowering therapies are not appropriate for the patient. Nalecol may provide additional, supportive assistance in managing cholesterol levels to address the persistent, unseen danger posed by residual high cholesterol, supporting patients in their therapeutic path toward vascular health management.


Managing Complex Genetic Disorders

Nalecol plays a role in managing rare, severe inherited conditions like Familial Hypercholesterolemia and Sitosterolemia. The practical benefit is in supporting the long-term management of pathological fat accumulation, which assists in mitigating the risk of associated severe complications in affected adults, children, and adolescents.

Quick Fact: Relief for Lipid Markers
Nalecol is used to help lower high LDL-C and Total Cholesterol, thereby supporting the patient's lipid management plan.

Regulatory References

  1. Ezetimibe: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Nalecol (Ezetimibe)

Official regulatory documents define specific populations for whom Nalecol is permitted, restricted, or contraindicated.

Contraindications and Restrictions

Nalecol use is contraindicated (must not be used) in patients with a known hypersensitivity to ezetimibe or its ingredients. Additionally, when Nalecol is used in combination with a statin, it is also contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases (liver enzymes) exceeding three times the upper limit of normal. Use with a statin is also contraindicated during pregnancy or lactation.

Use is not recommended in patients with moderate or severe hepatic impairment (liver dysfunction) due to unknown effects from increased exposure.

Age-Related Eligibility

Nalecol is generally approved for use in adults for all labeled indications. The medicine is approved for children and adolescents six years of age and older for Homozygous Familial Hypercholesterolemia (HoFH) and Sitosterolemia, and for those ten years of age and older for Heterozygous Familial Hypercholesterolemia. Safety and efficacy have not been established in children under six years of age. No dosage adjustment is required for older adults based on age alone.

Physiological Status

As monotherapy, Nalecol use during pregnancy should occur only if clearly necessary. Its use is generally not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Nalecol (ezetimibe), which are primarily classified based on their effect on systemic exposure and pharmacodynamic risk.

Documented Interaction Patterns

Interactions Altering Exposure (Pharmacokinetic): Co-administration with Cyclosporine causes a significant increase in the total plasma exposure (AUC) of ezetimibe, a change attributed to drug transporter interactions. Conversely, Cholestyramine—a bile acid sequestrant—reduces the systemic exposure of ezetimibe by approximately 55%.

Timing-Based Administration Rules: Due to the reduction in exposure caused by bile acid sequestrants, Nalecol must be administered at least 2 hours before or at least 4 hours after taking Cholestyramine to manage this effect.

Pharmacodynamic and Restricted Combinations: Combining Nalecol with Fibrates (other than fenofibrate) is not recommended by regulators. The co-administration of Fenofibrate carries a documented risk of increasing the potential for cholelithiasis. Post-marketing reports indicate that the addition of ezetimibe to stable therapy with Coumarin Anticoagulants (such as Warfarin) has been associated with an increase in the International Normalized Ratio (INR).

Population-Specific Caution: The use of Nalecol is generally not recommended in patients with moderate to severe hepatic impairment. This restriction stems from the known increase in systemic exposure of the drug in this population, which makes the effects of potential drug interactions unknown.

Mechanism of Action

Selective Blockade of Intestinal Cholesterol Uptake

Nalecol (Ezetimibe) works via a highly targeted, peripheral mechanism confined to the small intestine, where it functions as a selective inhibitor of the Niemann-Pick C1-Like 1 (NPC1L1) protein. This protein is a critical membrane transporter for sterols, and its functional blockade prevents the absorption of both dietary and biliary cholesterol from the gut lumen into the systemic circulation. This initial step modifies the intestinal cholesterol absorption pathway, resulting in a diminished net transport of cholesterol from the intestine.

Homeostatic Regulation and Increased Liver Clearance

The reduced delivery of cholesterol to the liver triggers a physiological imbalance, activating a compensatory homeostatic mechanism. The liver responds to its depleted internal sterol pool by upregulating Low-Density Lipoprotein (LDL) receptors on its cell surfaces. This systemic change increases the liver's functional rate of LDL-C particle removal from the bloodstream, which is the central physiological consequence of the drug's mechanism. The mechanism is partially limited by the liver’s compensatory response to increase its own cholesterol production.

Dosage and Administration Information

How to Use Nalecol

Nalecol (Ezetimibe) is prescribed based on standardized protocols that define the approach for its administration and dosing. This medication is exclusively used by the oral route in the form of a tablet.

Dosing and Frequency

The standard regimen for Nalecol in adults and adolescents is a fixed dose of 10 mg taken once daily. This consistency in dosage simplifies its use as a long-term therapy for managing cholesterol levels.

Administration Conditions

Instruction Detail
Timing in Relation to Meals Nalecol may be administered with or without food.
Co-administration with Sequestrants If taken alongside a bile acid sequestrant (another cholesterol medicine), Nalecol must be administered at least 2 hours before or 4 hours after the sequestrant.
Missed Dose Rule If a scheduled dose is missed, it should be taken as soon as possible, but it is instructed not to take two doses at the same time.

Population-Specific Usage

The standard 10 mg once-daily dose applies to children and adolescents who are 10 years of age and older. For older adults and patients with mild kidney problems, no dosage adjustment is generally necessary. However, the use of this medicine is not recommended for patients diagnosed with moderate or severe liver impairment due to potential accumulation concerns, reflecting a limitation defined in the prescribing information.

Procedural Summary

The core administration protocol dictates a once-daily oral intake of the 10 mg tablet, regardless of food consumption. This procedure is primarily constrained by the mandatory time separation required when combining the medicine with specific sequestrant therapies.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nalecol

The evidence for Nalecol (ezetimibe) was studied for its use across different research types, including large, randomized controlled trials and smaller studies focusing on rare genetic conditions. These studies monitored changes in blood markers and long-term health events to describe patterns observed in the populations studied.


Evidence for High Cholesterol and Mixed High Blood Fats

Research has extensively examined the use of Nalecol in adults with primary hypercholesterolemia, which refers to conditions involving elevated levels of "bad" cholesterol like LDL-C and Total Cholesterol. These investigations often involve two main scenarios: when Nalecol is evaluated in monotherapy, and when it is observed in combination with a statin medication.

Randomized Controlled Trials (RCTs) were used in research exploring how key blood lipid biomarkers changed over periods ranging from 8 to 12 weeks. These short-term studies provided context on how LDL-C levels evolved in the observed populations.

Research Outcomes Measured in Studies for High Cholesterol

Research also focused on long-term health events. Large, multi-year trials explored outcomes related to cardiovascular health, including the occurrence of Major Adverse Cardiovascular Events (MACE) such as heart attack (myocardial infarction) and stroke. The data describe patterns related to these events when Nalecol was used alongside a statin in high-risk patients. The reporting of long-term health events was tracked in the studies.


Evidence for Managing Rare Genetic Lipid Disorders

Nalecol was evaluated in studies focusing on two rare inherited conditions: Homozygous Familial Hypercholesterolemia (HoFH) and Homozygous Sitosterolemia. The research primarily consists of adding Nalecol to the patient's existing maximum treatment regimen. For HoFH, the research examined short-term changes in LDL-C and Total Cholesterol in adults, children, and adolescents. For homozygous sitosterolemia, the research describes measured changes in the plasma concentrations of the plant sterols, Sitosterol and Campesterol, and reported how physical signs evolved in the observed populations.


What Remains Uncertain and Areas for More Research

The majority of the long-term evidence for heart event outcomes applies only to the populations studied who were using Nalecol as an addition to a statin. There is limited information for long-term outcomes when Nalecol is used entirely on its own. The sample sizes were modest in the research for the rare genetic disorders, meaning that results apply only to the populations studied, and research does not determine individual predictions.

Key Studies & References

  1. Ezetimibe Added to Statin Therapy After Acute Coronary Syndromes (The IMPROVE-IT Trial)
  2. Label: EZETIMIBE tablet - DailyMed (Regulatory Monograph for Indications)
  3. Long-Term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial

Frequently Asked Questions (FAQ)

Common questions about Nalecol (FAQ)


Q: Does Nalecol treat the symptoms or the underlying cause?

A: This medication works by acting as a selective inhibitor of cholesterol absorption in the intestine. By blocking this pathway, it affects the body's method of taking in cholesterol, which in turn helps to lower elevated blood lipid levels.

Q: How quickly does Nalecol start working?

A: The drug is known to be rapidly absorbed by the body. According to official information, the measurable cholesterol-lowering effects—specifically the reduction in LDL-C—typically begin to be observed within approximately 2 weeks of starting treatment.

Q: Is hair loss a common side effect of Nalecol?

A: Hair loss (alopecia) is not listed among the commonly reported side effects in the official regulatory documents or clinical trial data.

Q: I saw a post online about weight gain with Nalecol—is that true?

A: Weight gain is not listed among the officially documented side effects in the clinical trial data for this medication. Side effects are officially classified by frequency (common, uncommon, etc.) based on regulatory documentation.

Q: Where can I find the official prescribing information for Nalecol?

A: Information about this drug can be located on official government health agency websites by searching for the active ingredient, Ezetimibe.

Q: Do I need to change my diet while taking Nalecol?

A: The drug is officially indicated for use in combination with a cholesterol-lowering diet. This means that dietary modifications are considered an important part of the overall treatment plan for managing elevated cholesterol.

Q: Does Nalecol require any special monitoring or blood tests?

A: Official warnings indicate that monitoring of liver enzyme tests may be required for patients taking this medication, especially in combination with a statin. Official documentation describes the need for monitoring before treatment and on a periodic basis, as determined by a healthcare provider.

Q: Is the evidence for Nalecol considered strong by medical bodies?

A: Official documentation describes the use of large-scale Randomized Controlled Trials (RCTs) in studying this medication. These studies monitored patients over multiple years to track changes in blood lipids and the occurrence of major cardiovascular events.

Q: What is the general success rate mentioned in the research for Nalecol?

A: Instead of providing a single 'success rate,' the efficacy of this drug is measured by the percentage reduction achieved in Low-Density Lipoprotein Cholesterol (LDL-C) and by data tracking the incidence of major adverse cardiovascular events in the study populations.

Q: Is Nalecol considered a controlled substance?

A: No. This medication is classified as a prescription-only medicine but is not scheduled as a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration (DEA).

Q: Do I need to take Nalecol forever?

A: Treatment for chronic conditions like elevated cholesterol is often long-term. The duration of therapy is based on a patient's treatment goals, and the full regimen is defined by the prescribing healthcare provider.

Q: Can Nalecol make me feel dizzy or lightheaded?

A: Dizziness has been reported as an undesirable effect of the drug, particularly in post-marketing reports or when the drug is used in combination with other cholesterol-lowering medicines.

Q: Does Nalecol interact with common over-the-counter pain medications?

A: Official drug interaction studies that have been conducted do not list common over-the-counter (OTC) pain medications such as ibuprofen or acetaminophen as having a clinically significant pharmacokinetic interaction with this drug.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Nalecol?

A: All vitamins, supplements, and herbal products should be reviewed with a healthcare provider. Red Yeast Rice, for example, may be discouraged due to overlap with statin effects and related safety concerns.

Q: Is it safe to drink alcohol in moderation while on Nalecol?

A: Official documents do not list a specific drug interaction with alcohol. However, patients who consume substantial quantities of alcohol or have a history of liver disease may face a higher risk for liver injury, particularly when the drug is used with a statin.

Q: Does Nalecol affect birth control pills?

A: Official drug interaction studies do not report that this medication has a significant effect on the concentrations of oral contraceptives (birth control pills).

Q: Can people with high blood pressure take Nalecol?

A: There is no contraindication for using this medicine in people with pre-existing high blood pressure. However, hypertension (high blood pressure) itself has been reported as an uncommon adverse reaction in some clinical studies.

Q: Does Nalecol have any known mental health side effects, like anxiety?

A: Regulatory documents list depression as an undesirable effect that has been reported, particularly in post-marketing experience. However, anxiety is not typically listed among the documented adverse reactions.

Q: What happens when I stop taking Nalecol?

A: Official information indicates that if the medication is discontinued, cholesterol levels may rise again. Any decision to stop treatment should be reviewed with a healthcare provider.

Q: Is Nalecol a generic drug or still under patent?

A: The active ingredient in this medication, Ezetimibe, is available in the generic form, as the original brand name product’s patent has expired.

Q: Does Nalecol cause dry mouth?

A: Yes, dry mouth has been reported as an uncommon side effect in clinical studies. Uncommon means it may affect less than 1 in 100 people.

Q: Can Nalecol make you more sensitive to the sun?

A: Official documentation on adverse reactions does not list photosensitivity (increased sun sensitivity) as a documented side effect of this medication.

Q: Is a metallic taste in the mouth reported as a side effect of Nalecol?

A: A metallic taste in the mouth is not listed among the documented adverse reactions in the official product information for this drug.

Q: How long does Nalecol stay in your system after stopping it?

A: The drug and its primary active metabolite have an elimination half-life of approximately 22 hours. This figure describes how long it takes for the drug to clear from the body.

Q: Are there known interactions between Nalecol and caffeine?

A: Regulatory studies indicate that this drug does not have a clinically significant effect on certain metabolic processes, including those that metabolize caffeine.

Q: Can Nalecol affect my ability to drive or operate machinery?

A: Official product information indicates that the drug is not expected to interfere with the ability to drive or use machinery. If side effects such as dizziness are experienced, caution is generally advised.

Q: Do official documents mention any risk of dependence with Nalecol?

A: Since the drug is not classified as a controlled substance, official regulatory documents do not list or mention a risk of physical dependence or abuse potential.

Q: Can Nalecol affect fertility or the ability to conceive?

A: Animal studies have shown no effect on male or female fertility. There is no evidence to suggest that taking the medication affects fertility in humans.

Q: Does taking Nalecol cause issues with sleep?

A: Sleep-related issues such as insomnia are not commonly or uncommonly listed in the documented adverse reactions in regulatory sources.

How should Nalecol be stored and disposed of?

Nalecol (ezetimibe) tablets must be stored according to official regulatory conditions to ensure stability and safety.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). The permitted temperature range is 15 C to 30 C (59 F to 86 F).
  • Protection: The product must be protected from moisture and light. Do not refrigerate or freeze the tablets.
  • Container and Safety: Keep the medicine in its original, tightly closed container and store it out of the sight and reach of children.

Disposal Instructions

Do not flush unused or expired Nalecol down the toilet or pour it down a drain. The official method for discarding the tablets is to follow local requirements and use a designated drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nalecol found in:

A-Z Index: